Characteristics and prognosis of bloodstream infection in patients with COVID-19 admitted in the ICU: an ancillary study of the COVID-ICU study

• Published in: Annals of intensive care Vol. 11; no. 1; p. 183
• Main Authors: Massart, Nicolas, Maxime, Virginie, Fillatre, Pierre, Razazi, Keyvan, Ferré, Alexis, Moine, Pierre, Legay, Francois, Voiriot, Guillaume, Amara, Marlene, Santi, Francesca, Nseir, Saad, Marque-Juillet, Stephanie, Bounab, Rania, Barbarot, Nicolas, Bruneel, Fabrice, Luyt, Charles-Edouard
• Format: Journal Article Web Resource
• Language: English
• Published: Cham Springer International Publishing 24.12.2021; Springer Nature B.V; SpringerOpen; Springer Science and Business Media Deutschland GmbH
• Subjects: Anesthesia & intensive care; Anesthesiology; Anesthésie & soins intensifs; Antiviral drugs; Cardiology and cardiovascular system; Coronaviruses; COVID-19; Critical Care and Intensive Care Medicine; Critical Care Medicine; Emergency Medicine; Emerging diseases; Human health and pathology; Human health sciences; Infectious diseases; Intensive; Intensive care; Life Sciences; Medical prognosis; Medicine; Medicine & Public Health; Mortality; Nosocomial infections; Pulmonology and respiratory tract; Sciences de la santé humaine; Severe acute respiratory syndrome coronavirus 2; Toxicology
• ISSN: 2110-5820; 2110-5820
• DOI: 10.1186/s13613-021-00971-w

Background Patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-COV 2) and requiring intensive care unit (ICU) have a high incidence of hospital-acquired infections; however, data regarding hospital acquired bloodstream infections (BSI) are scarce. We aimed to investigate risk factors and outcome of BSI in critically ill coronavirus infectious disease-19 (COVID-19) patients. Patients and methods We performed an ancillary analysis of a multicenter prospective international cohort study (COVID-ICU study) that included 4010 COVID-19 ICU patients. For the present analysis, only those with data regarding primary outcome (death within 90 days from admission) or BSI status were included. Risk factors for BSI were analyzed using Fine and Gray competing risk model. Then, for outcome comparison, 537 BSI-patients were matched with 537 controls using propensity score matching. Results Among 4010 included patients, 780 (19.5%) acquired a total of 1066 BSI (10.3 BSI per 1000 patients days at risk) of whom 92% were acquired in the ICU. Higher SAPS II, male gender, longer time from hospital to ICU admission and antiviral drug before admission were independently associated with an increased risk of BSI, and interestingly, this risk decreased over time. BSI was independently associated with a shorter time to death in the overall population (adjusted hazard ratio (aHR) 1.28, 95% CI 1.05–1.56) and, in the propensity score matched data set, patients with BSI had a higher mortality rate (39% vs 33% p  = 0.036). BSI accounted for 3.6% of the death of the overall population. Conclusion COVID-19 ICU patients have a high risk of BSI, especially early after ICU admission, risk that increases with severity but not with corticosteroids use. BSI is associated with an increased mortality rate.